Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 20501846)

1.

Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.

Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC.

Cancer Res. 2010 Jun 15;70(12):4795-800. doi: 10.1158/0008-5472.CAN-09-0851. Epub 2010 May 25.

2.

Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.

Kamihara J, Rana HQ, Garber JE.

Hum Mutat. 2014 Jun;35(6):654-62. doi: 10.1002/humu.22559. Review.

PMID:
24706533
3.

Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.

Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P.

Curr Opin Oncol. 2010 Jan;22(1):64-9. doi: 10.1097/CCO.0b013e328333bf00. Review.

PMID:
19952748
4.

Germline TP53 mutations and Li-Fraumeni syndrome.

Varley JM.

Hum Mutat. 2003 Mar;21(3):313-20. Review. Erratum in: Hum Mutat. 2003 May;21(5):551.

PMID:
12619118
5.

[Li-Fraumeni syndrome].

Frebourg T.

Bull Cancer. 1997 Jul;84(7):735-40. Review. French.

PMID:
9339200
6.

[Germline mutations of the p53 gene].

Frebourg T.

Pathol Biol (Paris). 1997 Dec;45(10):845-51. Review. French.

PMID:
9769948
7.

The Li-Fraumeni syndrome: an inherited susceptibility to cancer.

Evans SC, Lozano G.

Mol Med Today. 1997 Sep;3(9):390-5. Review.

PMID:
9302689
8.

Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Sorrell AD, Espenschied CR, Culver JO, Weitzel JN.

Mol Diagn Ther. 2013 Feb;17(1):31-47. doi: 10.1007/s40291-013-0020-0. Review.

9.

Li-Fraumeni Syndrome.

Schneider K, Zelley K, Nichols KE, Garber J.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015.
1999 Jan 19 [updated 2013 Apr 11].

10.

Li-Fraumeni syndrome: cancer risk assessment and clinical management.

McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G.

Nat Rev Clin Oncol. 2014 May;11(5):260-71. doi: 10.1038/nrclinonc.2014.41. Epub 2014 Mar 18. Review.

PMID:
24642672
11.

Potential of Advexin: a p53 gene-replacement therapy in Li-Fraumeni syndrome.

Nemunaitis JM, Nemunaitis J.

Future Oncol. 2008 Dec;4(6):759-68. doi: 10.2217/14796694.4.6.759. Review.

PMID:
19086841
12.

p53 and hereditary cancer.

Merino D, Malkin D.

Subcell Biochem. 2014;85:1-16. doi: 10.1007/978-94-017-9211-0_1. Review.

PMID:
25201186
13.

[Li-Fraumeni familial cancer syndrome: case report and review of the literature].

Tena Sanabria ME, Herrera Sánchez D, Hernández López J, Huicochea Montiel JC, Rodríguez A.

Acta Ortop Mex. 2007 Mar-Apr;21(2):99-104. Review. Spanish.

PMID:
17695766
14.

Population screening for cancer-related germline gene mutations.

Grann VR, Jacobson JS.

Lancet Oncol. 2002 Jun;3(6):341-8. Review.

PMID:
12107021
15.

Pediatric adrenocortical tumors: what they can tell us on adrenal development and comparison with adult adrenal tumors.

Lalli E, Figueiredo BC.

Front Endocrinol (Lausanne). 2015 Feb 18;6:23. doi: 10.3389/fendo.2015.00023. eCollection 2015. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk